This review outlines consensus-based recommendations for consideration of allogeneic hematopoietic cell transplantation (HCT) in primary myelofibrosis. Among the recommendations are that patients with intermediate-2- or high-risk disease and age <70 years be considered as candidates for allo-HCT. The authors recommend that patients with intermediate-1-risk disease and age <65 years be considered as candidates for allo-HCT if they present with either refractory, transfusion-dependent anemia, or a percentage of blasts in peripheral blood >2%, or adverse cytogenetics.
Review: Indications for Allo-HCT in Primary Myelofibrosis
Oct 2015